Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.57 |
| ▸ | HTR2C | P28335 | 5/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | TDP2 | O95551 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6719301 | 0.90 | HTR2A (0.57) | HTR2AHTR2CKCNH2HRH1HRH4 | |
| SCHEMBL6713978 | 0.79 | HTR2A (0.71) | HTR2AHTR2CPIM1 | |
| SCHEMBL6713843 | 0.78 | HTR2C (0.61) | HTR2AHTR2CHRH4PIM1 | |
| SCHEMBL6718446 | 0.78 | HTR2A (0.60) | HTR2AHTR2CPIM1 | |
| SCHEMBL6711279 | 0.77 | HTR2A (0.59) | HTR2AHTR2C | |
| SCHEMBL6711554 | 0.76 | HTR2A (0.58) | HTR2AHTR2C | |
| SCHEMBL6711419 | 0.76 | HTR2A (0.58) | HTR2AHTR2CHRH4HRH3PGR | |
| SCHEMBL6711262 | 0.76 | HTR2A (0.58) | HTR2AHTR2C | |
| SCHEMBL6716111 | 0.76 | HTR2C (0.59) | HTR2AHTR2C | |
| SCHEMBL6714402 | 0.76 | HTR2C (0.58) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040209870-A1 | Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds | ENNIS MICHAEL DALTON (US) | 2004-10-21 | — | — | US | claimed |
| US-6734301-B2 | 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY | 2004-05-11 | — | — | US | claimed |
| US-20020002161-A1 | Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds | PHARMACIA & UPJOHN COMPANY | 2002-01-03 | — | — | US | claimed |
| US-20040209870-A1 | Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds | ENNIS MICHAEL DALTON (US) | 2004-10-21 | — | — | US | disclosed |
| US-6734301-B2 | 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY | 2004-05-11 | — | — | US | disclosed |
| US-20020002161-A1 | Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds | PHARMACIA & UPJOHN COMPANY | 2002-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002161-A1 | Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds | HTR1D, HTR1A, HTR1E | HTR2A 18/4885HTR2C 7/4885KCNH2 1035/4885 |
| US-20040209870-A1 | Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds | HCRTR2, NR2C2, RCOR3 | HTR2A 1403/4885HTR2C 553/4885KCNH2 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.